SlideShare una empresa de Scribd logo
1 de 102
Descargar para leer sin conexión
Randomized trial seminar
0 Background
0 Experimental studies
0 Designs of RCT
0 Types of RCT
0 Steps in conducting RCT
0 Ethical issues
0 Pros & Cons
0 Example
0 Both in public health and in clinical practice, the
main objective is to modify the natural history of
disease so as to prevent or delay death or disability
and to improve the health of patient or the
population.
0 The challenge is to select the best available
preventive or therapeutic measure to achieve this
goal.
0 To do so, studies are carried out that determine the
value of these measures.
Galen(129-c.199ce) gave one of his potions to a lot of patients:
some recovered, some died. He thought that was evidence that
the potion worked.
All who drink of this treatment recover in short time, Except
those whom it did not help, who will die ,It is obvious, therefore,
that it fails only in incurable cases.
0 The problem with Galen’s line of reasoning is that no
experiment could disprove it . He could call any treatment
superior by claiming that evidence against it doesn’t count.
0 In 1537,AMBROISE PARÉ conducted unplanned trials in the
treatment of battle wounds.
0 One day after winning a battle, there were numerous wounded
for him to treat.
0 Due to lack of boiling oil which was a standard treatment at
that time, he used digestive made of egg yolk, rose oil &
turpentine and found it to work better than boiling oil.
0 Such trials have been the instruments of development of
medicine from a long time.
0 The first instance of random allocation of patients to experimental
and control conditions is attributed to James Lind, a naval surgeon,
in 1747.
0 Lind randomly assigned 12 sailors to 6 different treatments for
scurvy. The two patients who were given lemons and oranges
recovered most quickly, suggesting a beneficial effect of citrus.
Randomization was
Contributed by statistician
R.A. Fisher in agriculture
in 1923.
Randomized plots of crops
to receive different
treatments
0 The first RCT in medicine is credited to Sir A. Bradford Hill,
an epidemiologist for England's Medical Research Council.
0 The trial, published in the British Medical Journal in 1948,
tested whether streptomycin is effective in treating
tuberculosis.
0 First, he simply alternated the assignment of hospital
admissions to drug versus control .Later he recognized it led
to selection bias because the sequence was too easy to predict.
That realization led to the use of a random numbers table to
generate the numeric series by which patients would be
assigned to conditions.
0 Involve an active attempt
0 Types
 With patients as unit of studyCLINICAL TRIALS
With healthy people as unit of
study
FIELD TRIALS/
COMMUNITY
INTERVENTION
STUDIES
With communities as unit of
study
COMMUNITY TRIALS
0 Types
RANDOMIZED
CONTROLLED
TRIALS
Those involving a process of
‘RANDOM ALLOCATION’
Non RANDOMIZED
CONTROLLED
TRIALS
Those departing from ‘strict
randomization’ for practical
purposes
a. Cross-sectional comparison:
e.g. to comparable
communities or groups
b. Temporal comparison:
e.g. before and after the
intervention
c. Combinations of the above:
e.g. time-series analysis in
community trial.
In a randomized controlled trial,
Participants are assigned to treatment conditions at random
(i.e., they have an equal probability of being assigned to any
group).
Procedures are controlled to ensure that all participants in all
study groups are treated the same except for the factor that is
unique to their group. The unique factor is the type of
intervention they receive.
Primary goal
0 to test whether an
intervention works by
comparing it to a control
condition, usually either
no intervention or an
alternative intervention.
Secondary goals may include:
0 identify factors that
influence the effects of the
intervention (i.e.,
moderators)
0 understand the processes
through which an
intervention influences
change (i.e., mediators or
change mechanisms that
bring about the intervention
effect)
Study
population
Current
interventio
n
Improve
Do not
Improve
New
Interventio
n
Improve
Do not
Improve
R
A
N
D
O
M
IZ
A
TI
O
N
0 Concurrent parallel study design
0 Cross-over type of study design
0 Factorial design
0 Cluster design
0 Classical clinical trial
approach
0 Two study groups
0 Assumption of ‘no carryover
effects’ is difficult to test
0 Needs to determine appropriate
length of washout period.
0 “Period”effects : Progression of
disease, Dropouts
0 Will patient do better on drug A or
drug B?
0 Removes “patient effect” reducing
variability and increasing precision
of estimation
0 Major concern: interaction of
interventions
0 Patients must be willing and able to
take any of the treatment
combinations
0 Optimal dose modification strategy
for toxicity may be hard to
determine
0 Evaluates multiple factors
simultaneously
0 Groups or clusters randomly
assigned, not individuals. E.g. :
villages, classrooms , platoons
0 focus on effectiveness,outcomes
under conditions of actual use.
0 more appropriate for the
evaluation of interventions such
as family-based dietary
interventions,community-based
health promotion initiatives
0 or educational interventions.
0 Clinical trials
0 Preventive trials
0 Risk factor trials
0 Cessation experiments
0 Trial of etiological agents
0 Evaluation of health services
1. Drawing up a protocol
2. Selecting reference and experimental populations
3. Allocation of study subjects: Randomization
4. Intervention / manipulation
5. Follow –Up
6. Assessment of Outcome
0 One of the essential feature of RCT is that it is
conducted under a strict Protocol.
0 Once protocol is evolved, it should be strictly adhered to
throughout the study.
Prevents bias and reduces source of errors in the
study.
0 Preliminary or pilot test runs of protocol can be held
so see whether it contains any flaw.
0 Final version of protocol should be agreed upon by all
concerned before the trial begins.
0 Aims & Objectives of the study
0 Questions to be answered
0 Criteria for selection of study & control group
0 Size of Sample
0 Procedure for allocation of subjects into study &
control Group
0 Interventions to be applied-when ,where ,how and
what kind of subjects
0 Standardization of working procedures and schedules
0 Responsibilities of parties involved in trial
0 Evaluation of outcome of study
I. Reference /Target
Population:
 It is the population to
which findings of the trial
,if found successful , are
applicable.
 e.g. whole population,
population of school
children, population of a
city, industrial workers or
social groups
II. Experimental /Study
Population:
 derived from reference
population.
 Ideally, it should be chosen
randomly from reference
population so that it is
representation of reference
population.
Otherwise it may not be possible
to generalize the findings of the
study to reference population.
0 Inclusion & exclusion criteria : for determining who will or
will not be included in the study must be spelled out with great
precision, and in writing.
To ensure the replicability by others, just like with laboratory
experiments
0 To derive a causal inference regarding relationship of
intervention and outcome, comparison is important.
0 Types of controls :
Historical
Simultaneous nonrandomized controls
Randomized controls
0 Comparison group from past.
0 We go back to records of patients who were treated before
new treatment became available.
0 simple
Demerit:
0 Comparability can not be assured
0 Quality : Data for medical purpose not for research purpose
0 Changes in many factors over calendar time
0 Recall bias
0 Day of month of admission-odd/even days
0 Alternate assignment into study &control group
Predictable by investigator- selection bias
0 Randomization - a statistical procedure
by which the participants are allocated to
“Study” and “Control” groups.
0 The critical element of randomization is
the unpredictability of the next
assignment.
0 It makes RCT the gold standard design
for performing clinical trials.
Flipping a coin?
Rolling dice?
Shuffling cards?
Table of random numbers
computer random number
generators
• Random
• Reproducible
Preferable & recommended
• Random but tempt investigators
toward non-randomness
• Adequate methods but not
optimal
• Cannot be checked – no audit
trail
Not recommended
0 the probability of being
assigned to any
intervention stays
constant over the course
of the trial
0 the allocation probability
changes in response to the
balance, composition, or
outcomes of the groups
0 controversial because they
allocate patients not purely at
random
0 Aim: increase the sample's
probability of being assigned
to the best treatment
FIXED ALLOCATION
PROCEDURES
ADAPTIVE PROCEDURES
1. Simple(complete)
randomization
2. Permuted block
randomization
3. Balanced permuted
block randomization
4. Stratified randomization
1. Minimization Adaptive
Randomization
i. Biased Coin
Randomization
ii. Urn Randomization
2. Response Adaptive
Randomization
i. "Play-the-winner"
procedure
FIXED ALLOCATION
PROCEDURES
ADAPTIVE PROCEDURES
0 Elementary form of randomization, in which, every time when
there is an eligible participant, the investigator flips a coin to
determine whether the participant goes into the intervention or
control group.
0 A limitation is that random assignment is truly random.
A random process can result in the study winding up with
different numbers of subjects in each group. This is more
likely to happen if sample size is small
• Characters of ‘A completely random sequence of digits’
• Each digit occurs equally frequently in the whole sequence
• Adjacent (set of) digits are completely independent of one
another
• A table of random digits
• Behaves as a finite section from a completely random series
• Randomness is a property of the table as a whole
• Different numbers in the table are independent
00–04 05–09 10–14 15–19
00 56348 01458 36236 07253
01 09372 27651 30103 37004
02 44782 54023 61355 71692
03 04383 90952 57204 57810
04 98190 89997 98839 76129
05 16263 35632 88105 59090
06 62032 90741 13468 02647
07 48457 78538 22759 12188
08 36782 06157 73084 48094
09 63302 55103 19703 74741
Take Any Direction
…have to mention
this chosen
direction in
procedureMention
corresponding row
& column in
procedure
 Suppose we want to compare 2 treatments(A & B)
Random Number Table can be used in a no. of ways:
a) we will consider every odd number an assignment to
A and every even number an assignment to B
b) we could say that digits 0 to 4 would be treatment A,
and digits 5 to 9 treatment B.
c) If we are studying three groups, we could say that
digits 1 to 3 are treatment A, digits 4 to 6 treatment
B, digits 7 to 9 treatment C, and digit 0 would be
ignored.
d) Prepare a series of opaque envelopes that are
numbered sequentially on the outside: 1, 2, 3, 4, 5,
and so on.
542-04-#37
0 Simple randomization does not guarantee balance over time
in each realization.
0 Patient characteristics can change during recruitment (e.g.
early pts sicker than later).
0 Restricted randomizations guarantee balance
1. Permuted-block
2. Biased coin (Efron)
3. Urn design (LJ Wei)
0 Blocked randomization reduces the risk that different numbers
of people will be assigned to the treatment (T) and control (C)
groups.
0 Patients are randomized by blocks.
0 The order is chosen randomly at the beginning of the block.
0 In randomly permuted blocks, there are several block sizes
(e.g., 4, 6, and 8), and the block size and specific order are
chosen randomly at the beginning of each block.
Example
0 Block size 2m = 4
2 Trts A,B }  4C2 = 6 possible
0 Write down all possible assignments
0 For each block, randomly choose one of the six possible
arrangements
0 {AABB, ABAB, BAAB, BABA, BBAA, ABBA}
ABAB BABA ......
Pts 1 2 3 4 5 6 7 8 9 10 11 12
Advantage
0 A balance in the number
of cases assigned to T
versus C at any point in
the trial (which could be
valuable if the trial needs
to be stopped early).
Disadvantage
0 with fixed blocks,
predictability of the group
assignment of patients
being randomized late in
the block by research staff .
reduced by using the
method of randomly
permuted blocks and blind
ing of research staff to the
randomization process .
0 To ensure that the treatment and control groups are balanced
on important prognostic factors that can influence the study
outcome (e.g., gender, ethnicity, age, socioeconomic status).
0 Before doing the trial, the investigator decides which strata are
important and how many stratification variables can be
considered given the proposed sample size.
0 A separate simple or blocked randomization schedule is
developed for each stratum.
0 Large trials often use randomly permuted blocks within
stratification groups.
Stratified Randomisation
o Minimization corrects (minimizes) imbalances that arise over
the course of the study in the numbers of people allocated to
the treatment and control.
o An attempt to resolve the problem of empty strata when
trying to balance on many factors with a small number of
subjects
o Balances Trt assignment simultaneously over many strata.
o Used when the number of strata is large relative to sample
size as stratified randomization would yield sparse strata.
o Logistically more complicated
o In this procedure, if the imbalance in treatment assignments
passes some threshold, the allocation is changed from chance
to a bias in favor of the under-represented group.
o For example... If after 10 randomizations, there are 7 patients
assigned to intervention and 3 assigned to control, the coin
toss will become biased.
o Then, rather than having 50/50 chance of being assigned to
either condition, the next patient will be given a 2/3 chance of
being assigned to the under-represented condition and a 1/3
chance of being assigned to the overrepresented one.
o This procedure requires keeping track of imbalances
throughout the trial. In smaller trials, imbalances can still
result
0 This procedure tries to correct imbalances after each
allocation.
0 For example...
0 The investigator starts with off with an urn containing a red
ball and a blue ball to represent each condition.
0 If the first draw pulls the red ball, then the red ball is replaced
together with a blue ball, increasing the odds that blue will be
chosen on the next draw. This continues, replacing the chosen
ball and one of the opposite color on each draw.
0 The procedure works best at preventing imbalance when final
sample size is small.
542-04-#46
0 Stratified Randomization
0 Covariate Adaptive
0 Pocock & Simon
542-04-#47
0Goal is to balance on a number of factors but with "small"
numbers of subjects
0Example .., if at some point Trt A has more older patients that Trt
B, next few older patients should more likely be given Trt B until
"balance" is achieved
0Several risk factors can be incorporated into a score for degree of
imbalance B(t) for placing next patient on treatment t (A or B)
0More complicated to implement
Study type Randomization
Large studies Blocked
Large, Multicentre studies Stratified by centre
Small studies Blocked and Stratified
by centre
Large number of
Prognostic factors
Minimization
Large studies Stratified analysis
without stratified
randomization
• Actual randomization should be delayed until just prior to
initiation of therapy after consenting.
• This prevents randomizing participants who drop out
before participating in any of the study.
• This is important because everyone who gets randomized
needs to be included in the study's analysis.
1. Sequenced sealed envelopes (prone to tampering!)
2. Sequenced bottles/packets
3. Phone call to central location
- Live response
- Voice Response System
4. One site PC system
5. Web based
Best plans can easily be messed up in the implementation
0 Allocation concealment means that the
person who generates the random assignment
remains blind to what condition the person
will enter.
0 Preferably, randomization should be
completed by someone who has no other
study responsibilities. Often, the study
statistician assumes this role.
0 If allocation is not concealed, research staff is
prone to assign "better" patients to
intervention rather than control, which can
bias the treatment effect upward by 20-30%
• Deliberate application or withdrawal or reduction of the
suspected causal factor as laid down in the protocol
• This manipulation creates :
Independent variable (drug, vaccine or a new procedure):
whose effect is determined by measurement of final
outcome.
Dependent variable: final outcome (incidence of disease ,
survival time , recovery time)
0 Prognostic profile at entry
0 Treatment (Assigned & Received)
0 Follow-up
 Attrition
0 Outcome
 Outcome measurement
 Reliability and validity of outcome measures
0 Attrition: refers to a rate of loss of
participants from the study that differs
between the intervention and control
groups.
0 It may compromise
 internal validity by altering the random composition
of groups and their equivalence.
 statistical validity by reducing sample size and
power or by systematically altering the variability
within samples.
 External validity due to the potential for attrition to
limit the generalizability of results to only those who
are retained in a study.
Randomized trial seminar
0 An adverse event (AE) is an undesirable health occurrence
that occurs during the trial and that may or may not have a
causal relationship to the treatment.
0 A serious adverse event (SAE) is defined as something life-
threatening, requiring or prolonging hospitalization and/or
creating significant disability.
0 E.g. A suicide attempt -- an SAE in a study of any treatment.
0 The SAE needs to be reported regardless of whether it bears
any relationship to the treatment or the problem being studied
0 Depending on the severity and frequency of adverse events,
investigators and data safety monitors may have to decide to
terminate the trial prematurely.
Every Adverse event needs to be reported!
0 Which participants will be analyzed?
 Intention to treat
 Per protocol analysis
0 Subgroup Analyses
0 Statistical Power of study
0 Data Analytic Techniques
 Continuous Outcome Variables
 Categorial Outcome Variables
0 Basic Principle - “As randomized, so analyzed”
0 Includes all randomized patients in the groups to which they
were randomly assigned, regardless of their adherence with
the entry criteria, regardless of the treatment they actually
received, and regardless of subsequent withdrawal from
treatment or deviation from the protocol…..(Lloyd) Fisher et
al., 1990.
0 The ITT analysis addresses the question of pragmatic
hypothesis– the effectiveness of therapy i.e whether the study
treatment, if made available to the population, would be
superior to an alternative intervention.
Randomized trial seminar
0 the opposite end of the spectrum from ITT analysis
0 includes in the analysis only those cases who completed
treatment.
0 Its results represent the best case treatment results that could
be achieved if the study sample were retained and remained
compliant with treatment.
0 Should not be used alone/main analysis
Randomized trial seminar
0 Planned subgroup analyses. In a few instances, a study may
have been designed and powered to test whether a treatment
works better for one demographic group (e.g., females) than
another (e.g., males). In that case, testing a hypothesized
treatment by demographic group interaction would be a
primary aim that definitely needs be tested.
0 Exploratory subgroup analyses. More often, many different
treatment-by-subgroup interactions will be explored. Those
analyses can support hypothesis generation. The important
caveat is the need to remember that unplanned subgroup
analyses are done in the context of discovery rather than
confirmation. Any findings require replication in another trial.
0 Power is ability to find a difference when a real difference
exists.
0 The power of a study is determined by three factors:
 Alpha level.
 Sample size.
 Effect size:
• Association between DV and IV
• Separation of Means relative to error variance.
0 Sometimes we will incorrectly fail to reject the null hypothesis
– a type II error.
0 There really is an effect but we did not find it
0 Statistical power is the probability of detecting a real effect
0 More formally, power is given by:
1- 
where  is the probability of making a type II error
0 In other words, it is the probability of not making a type II
error
0 By making alpha less strict, we can increase power.
(e.g. p < 0.05 instead of 0.01)
0 However, we increase the chance of a Type I error.
0 One of the most useful aspects of power analysis is the
estimation of the sample size required for a particular study
0 Too small a sample size and an effect may be missed
0 Too large a sample size too expensive a study
0 Different formulae/tables for calculating sample size are
required according to experimental design
Randomized trial seminar
Randomized trial seminar
0 n = the sample size required in each group (double this for
total sample)
0 σ = standard deviation, of the primary outcome variable
0 δ= size of difference of clinical importance
0 π 1 = first proportion
0 π 2 = second proportion
0 zơ/2=depends on desired significance level
0 Zβ=depends on desired power
0 As the separation of
means increases, the
power of study increases.
0 As the variability about a
mean decreases power
also increases
Continuous outcome
measures((e.g. symptom
severity)
0 Analysis of Variance
(ANOVA) and its Variants
and Extensions
Alternative Analyses
0 Latent Growth Models
0 Growth Mixture Models
0 Multi-level Models
Categorial outcome
measures(e.g. being
hospitalized or quitting
smoking )
0 Generalized estimating
equations (GEE)
0 Survival analysis
• Dichotomization: Common analyses of RCT data require
outcomes to be classified as either "present" or "absent."
• Some outcomes such as death, stroke, or pregnancy are
naturally dichotomous (present or not).
• Sometimes events are dichotomized as a "success" or a
"failure" instead of "present" and "absent."
• Other outcomes that are naturally continuous (e.g., length of
hospital stay, blood pressure, pain score) can be dichotomized
by the selection of a “cutoff” score that separates successes
from failures.
• A "two by two" table often summarizes results
Blinding is an attempt to reduce bias arising out of errors
of assessment
a) Open trials:All participants and investigators know who is
getting which interventionE.g. medical vs. surgical treatments
b) Single blind trial: Participant not aware
c) Double blind trial: Neither doctor/investigator nor the
participant is aware.
d) Triple blind trial: Doctor/investigator , participant and the
person analyzing the data are all not aware of the assigned tt
Concealment of
allocation Blinding/Masking
0 to protect the randomization
process before the subject
enters the trial.
0 ALWAYS feasible
0 If not done, results in
selection bias(treatment
assignment is no longer truly
random)
0 After trial begins.
0 Blinding is not always feasible
0 If not done, can result in
patients biasing their responses
because of their knowledge of
treatment;
biased outcome assessment
because investigators have
knowledge of treatment
0 Estimation with Statistical Significance Testing
0 Assessing the Effect Size of an Intervention
0 Assessing Clinical Significance
Estimation with Statistical Significance Testing
0 Whether the effect of a treatment reaches a conventional
significance level (p <.05) depends heavily on factors such as
sample size.
Assessing the Effect Size of an Intervention
0 An effect size describes the magnitude of an intervention's
effect on the study outcome.
0 In the case of RCTs, the effect size represents the magnitude
of the difference between the control and intervention
conditions on a key outcome variable adjusted for the standard
deviation of either group.
Assessing Clinical Significance
0 When testing interventions that address health problems
The proportion of patients who move from exhibiting clinical
or dysfunctional levels of symptoms/behavior to functional
levels.
The Number Needed to Treat (NNT) expresses the number of
patients who need to receive the intervention to produce one
good outcome compared to control. NNT is a widely used
index of clinical significance
NNT= 1_ _____
(Rate in untreated gp)-(Rate in treated gp)
Assessing Clinical Significance
0 When testing interventions that address health problems
0 Once outcomes have been dichotomized, six statistical
measures are used to describe the treatment effect:-
• Control Event Rate (CER) & Experimental Event Rate
(EER)
• Absolute Risk Reduction (ARR) & Number Needed to
Treat (NNT)
• Relative Risk (RR) & Relative Risk Reduction (RRR)
Assessing Clinical Significance
0 CER = number of events in ctrl group/number of subjects in
ctrl group
0 EER = number of events in exp group/number of subjects in
exp group
0 ARR = CER – EER
0 The Number Needed to Treat (NNT) expresses the number of
patients who need to receive the intervention to produce one
good outcome compared to control. NNT= 1/ARR
0 RR represents the fraction of the original risk that remains with
intervention.RR=EER/CER
0 RRR represents the fraction of the original risk that is removed
with intervention.RRR=ARR/CER
CER & EERExp
(MgSO4)
Ctrl
(placebo)
Row
totals:
CP (+) 20 38 58
CP (-) 1021 1057 2078
Column
totals: 1041 1095 2136
Interpretation:
3.5% of the infants born in the control
group (without MgSO4) developed
moderate to severe cerebral palsy.
CER =
number of events in ctrl group
number of subjects in ctrl group
CER =
38
1095
= 0.035 = 3.5%
Interpretation:
1.9% of the infants born in the
experimental group (with MgSO4)
developed moderate to severe
cerebral palsy.
EER =
number of events in exp group
number of subjects in exp group
EER =
20
1021
= 0.019 = 1.9%
Control Event Rate
Experimental Event Rate
ARR & NNTExp
(MgSO4)
Ctrl
(placebo)
Row
totals:
CP (+) 20 38 58
CP (-) 1021 1057 2078
Column
totals: 1041 1095 2136
Interpretation:
Use of MgSO4 reduced the rate of
moderate to severe cerebral palsy by
1.6 percentage points.
Interpretation:
Between 62 and 63 pre-term mothers
need to be treated in order to avoid
one additional case of moderate to
severe cerebral palsy.
NNT=
1
ARR
NNT =
1
0.016
= 62.5
Absolute Risk Reduction
Number Needed to Treat
ARR = CER – EER
ARR = 3.5% – 1.9%
ARR = 1.6%
Notice how the units for CER & EER are "events per person" and the units for NNT is
"people per event." This matches the intuitive interpretation of ARR & NNT.
RR & RRRExp
(MgSO4)
Ctrl
(placebo)
Row
totals:
CP (+) 20 38 58
CP (-) 1021 1057 2078
Column
totals: 1041 1095 2136
Interpretation:
Use of MgSO4 reduced the risk of
moderate to severe CP by 46% of its
original value.
CER
RRR =
ARR
0.035
0.016
RRR = = 0.46 = 46%
Relative Risk
Relative Risk Reduction
Interpretation:
Use of MgSO4 reduced the risk of
moderate to severe CP to 54% of its
original value.
CER
RR=
EER
0.035
0.019
RR = = 0.54 = 54%
RR represents the fraction of the original risk that remains with MgSO4.
RRR represents the fraction of the original risk that is removed with MgSO4.
Randomized trial seminar
Randomized trial seminar
0 The Consolidated Standards of Reporting Trials (CONSORT)
has become the gold standard for reporting the results of
RCTs.
0 A checklist and flow diagram.
0 first published in 1996 and updated in 2001 and 2010.
0 Extensions of the CONSORT Statement have been developed
for other types of study designs, interventions and data.
Randomized trial seminar
Randomized trial seminar
Randomized trial seminar
0 Investigators are responsible to uphold ethical standards and
guidelines
0 Declaration of Helsinki. Developed by the World Medical
Association, this set of ethical principles guides medical
researchers in conducting research on human subjects.
Some procedures for safeguarding human subjects include:
0 Informed consent procedures
0 Procedures to safeguard confidentiality
0 Protocols to preserve safety and address adverse events
0 Reporting study results
0 Random assignment and the use of a control condition ensure
that any extraneous variation not due to the intervention is
either controlled experimentally or randomized. That allows
the study's results to be causally attributed to differences
between the intervention and control conditions.
0 In sum, the use of an RCT design gives the investigator
confidence that differences in outcome between treatment and
control were actually caused by the treatment, since random
assignment (theoretically) equalizes the groups on all other
variables.
Drawbacks of conducting an RCT are:
0 Time- and energy- intensive, Expensive
0 Losses to follow-up, lack of perfect blinding, and other
problems often affect RCTs in the field of public health,
0 “effect modification”--when the intervention–outcome
association varies according to the presence of external
characteristics.
0 “behavioral effect modification,”(institutional, provider, and
recipient behaviors)“biological effect modification.”
0Unnecessary if:
0 Clearly successful intervention
0 Previous RCT’s or meta-analyses
0Impractical when:
0 Unethical to randomise
0 Large number needed
0Inappropriate when:
0 Looking at prognosis
0 Looking at validity of diagnostic tests
0 Looking at quality of care
Intervention : Modeled On The Baby-friendly
Hospital Initiative
Randomized trial seminar
0 two-week zinc therapy for diarrhoea on morbidity and mortality due to
diarrhoea and ALRI in a community-based cluster randomized trial (3) in the
Matlab field area of ICDDR,B: Centre for Health and Population Research in
Bangladesh. Thirty service areas (clusters) around Matlab Treatment Centre
each with about 200 children aged 3-59 months were randomly allocated to
intervention or comparison areas. One community health worker served each
cluster
0 In this trial, the availability of zinc supplements, along with ORT and
appropriate education programmes, was associated with significantly higher
use of ORT and lower use of antibiotics.
J HEALTH POPUL NUTR 2004 Dec;22(4):440-442
0 “Evidence-based public health” calls for a solid knowledge
base on disease frequency and distribution, on the
determinants and consequences of disease, and on the safety,
efficacy, and effectiveness of interventions and their costs.
0 Existing standards and methods must be adapted to meet the
methodological challenges of evaluating large-scale public
health interventions.
Randomized trial seminar
0 Instead of having a “no treatment” control, equivalence trials test
whether a new intervention is as good as (or not worse than) an
established treatment with proven efficacy.
0 New intervention may have some advantage (convenience, cost)
over established, but is it at least as efficacious?
0 People may be carrying out equivalence trials without
realising it.
0 Analysis with respect to a pre-stated margin of non-inferiority
(smallest clinically interesting difference)
0 ITT analysis may increase risk of type 1 error
0 Choice of outcomes important
Piaggio et al., 2006, JAMA,295,1152-1160
0 Need to reference established efficacy of “standard” treatment
0 Hypotheses should be framed in terms of non-inferiority
0 “Margins of equivalence” should be reported
0 Various approaches used:
0Checklist approach
0Quality scoring system approach
0 Quality scores are complicated and tend to vary depending
on the instrument used –so, not encouraged

Más contenido relacionado

La actualidad más candente

Cross sectional study-dr.wah
Cross sectional study-dr.wahCross sectional study-dr.wah
Cross sectional study-dr.wahMmedsc Hahm
 
Randomized controlled trial: Going for the Gold
Randomized controlled trial: Going for the GoldRandomized controlled trial: Going for the Gold
Randomized controlled trial: Going for the GoldGaurav Kamboj
 
Meta analysis
Meta analysisMeta analysis
Meta analysisSethu S
 
Blinding in clinical trilas
Blinding in clinical trilas Blinding in clinical trilas
Blinding in clinical trilas Tarek Tawfik Amin
 
Sample determinants and size
Sample determinants and sizeSample determinants and size
Sample determinants and sizeTarek Tawfik Amin
 
Experimental Study
Experimental StudyExperimental Study
Experimental StudyMukesh Kumar
 
Biostatistics in Clinical Research
Biostatistics in Clinical ResearchBiostatistics in Clinical Research
Biostatistics in Clinical ResearchAbhaya Indrayan
 
Blinding in Clinical Trials
Blinding in Clinical TrialsBlinding in Clinical Trials
Blinding in Clinical TrialsTerry Shaneyfelt
 
Observational descriptive study: case report, case series & ecological study
Observational descriptive study: case report, case series & ecological studyObservational descriptive study: case report, case series & ecological study
Observational descriptive study: case report, case series & ecological studyPrabesh Ghimire
 
Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Vikash Keshri
 
Cross sectional study by Dr Abhishek Kumar
Cross sectional study by Dr Abhishek KumarCross sectional study by Dr Abhishek Kumar
Cross sectional study by Dr Abhishek Kumarak07mail
 
Error, bias and confounding
Error, bias and confoundingError, bias and confounding
Error, bias and confoundingMitasha Singh
 
Observational Studies and their Reporting Guidelines
Observational Studies and their Reporting GuidelinesObservational Studies and their Reporting Guidelines
Observational Studies and their Reporting Guidelineskopalsharma85
 
Randomized clinical trials
Randomized clinical trialsRandomized clinical trials
Randomized clinical trialsimprovemed
 

La actualidad más candente (20)

Cross sectional study-dr.wah
Cross sectional study-dr.wahCross sectional study-dr.wah
Cross sectional study-dr.wah
 
Randomized controlled trial: Going for the Gold
Randomized controlled trial: Going for the GoldRandomized controlled trial: Going for the Gold
Randomized controlled trial: Going for the Gold
 
Meta analysis
Meta analysisMeta analysis
Meta analysis
 
Experimental study design.pptx
Experimental study design.pptxExperimental study design.pptx
Experimental study design.pptx
 
5. cohort studies
5. cohort  studies5. cohort  studies
5. cohort studies
 
Blinding in clinical trilas
Blinding in clinical trilas Blinding in clinical trilas
Blinding in clinical trilas
 
Sample determinants and size
Sample determinants and sizeSample determinants and size
Sample determinants and size
 
Experimental Study
Experimental StudyExperimental Study
Experimental Study
 
Biostatistics in Clinical Research
Biostatistics in Clinical ResearchBiostatistics in Clinical Research
Biostatistics in Clinical Research
 
Blinding in Clinical Trials
Blinding in Clinical TrialsBlinding in Clinical Trials
Blinding in Clinical Trials
 
Observational descriptive study: case report, case series & ecological study
Observational descriptive study: case report, case series & ecological studyObservational descriptive study: case report, case series & ecological study
Observational descriptive study: case report, case series & ecological study
 
Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)
 
Bias in clinical research
Bias in clinical research Bias in clinical research
Bias in clinical research
 
Cross sectional study by Dr Abhishek Kumar
Cross sectional study by Dr Abhishek KumarCross sectional study by Dr Abhishek Kumar
Cross sectional study by Dr Abhishek Kumar
 
Rct
RctRct
Rct
 
Comparative observational studies
Comparative observational studies Comparative observational studies
Comparative observational studies
 
Error, bias and confounding
Error, bias and confoundingError, bias and confounding
Error, bias and confounding
 
Observational Studies and their Reporting Guidelines
Observational Studies and their Reporting GuidelinesObservational Studies and their Reporting Guidelines
Observational Studies and their Reporting Guidelines
 
Randomized clinical trials
Randomized clinical trialsRandomized clinical trials
Randomized clinical trials
 
cohort study
 cohort study cohort study
cohort study
 

Similar a Randomized trial seminar

Clinical trial : Types and Design (Pharmacovigilance)
Clinical trial : Types and Design (Pharmacovigilance)Clinical trial : Types and Design (Pharmacovigilance)
Clinical trial : Types and Design (Pharmacovigilance)Ayush Roy
 
EXPERIMENTAL EPIDEMIOLOGY
EXPERIMENTAL EPIDEMIOLOGYEXPERIMENTAL EPIDEMIOLOGY
EXPERIMENTAL EPIDEMIOLOGYDr. Thaher
 
Randomized Controlled Trials
Randomized Controlled TrialsRandomized Controlled Trials
Randomized Controlled TrialsNabeela Basha
 
clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and designUttara Joshi
 
6-study designs.pptx
6-study designs.pptx6-study designs.pptx
6-study designs.pptxIbrahimKhlil1
 
Randomized Controlled Trial
Randomized Controlled Trial Randomized Controlled Trial
Randomized Controlled Trial Sumit Das
 
Randomized CLinical Trail
Randomized CLinical TrailRandomized CLinical Trail
Randomized CLinical Trailamitakashyap1
 
Experimental Studies
Experimental StudiesExperimental Studies
Experimental StudiesAbhijit Das
 
Surgical_audit_&_research_mm (1).ppt
Surgical_audit_&_research_mm (1).pptSurgical_audit_&_research_mm (1).ppt
Surgical_audit_&_research_mm (1).pptSofiaJohn5
 
Analytic upto surviellance
Analytic upto surviellanceAnalytic upto surviellance
Analytic upto surviellancekaleabtegegne
 
8-Clinical Trial Studies
8-Clinical Trial Studies8-Clinical Trial Studies
8-Clinical Trial StudiesResearchGuru
 
biostatists presentation
biostatists presentationbiostatists presentation
biostatists presentationAnil kumar
 
Epidemiological concept
Epidemiological conceptEpidemiological concept
Epidemiological conceptsushantkarki4
 
Blinding in RCT the enigma unraveled
Blinding in RCT the enigma unraveledBlinding in RCT the enigma unraveled
Blinding in RCT the enigma unraveledMANVEER SINGH
 
Random control trial RCT community medicine .pptx
Random control trial RCT community medicine  .pptxRandom control trial RCT community medicine  .pptx
Random control trial RCT community medicine .pptxAkshayRaj781072
 
4.1 case-control and cohort.pdf
4.1 case-control and cohort.pdf4.1 case-control and cohort.pdf
4.1 case-control and cohort.pdfmergawekwaya
 

Similar a Randomized trial seminar (20)

Clinical trial : Types and Design (Pharmacovigilance)
Clinical trial : Types and Design (Pharmacovigilance)Clinical trial : Types and Design (Pharmacovigilance)
Clinical trial : Types and Design (Pharmacovigilance)
 
EXPERIMENTAL EPIDEMIOLOGY
EXPERIMENTAL EPIDEMIOLOGYEXPERIMENTAL EPIDEMIOLOGY
EXPERIMENTAL EPIDEMIOLOGY
 
Randomized Controlled Trials
Randomized Controlled TrialsRandomized Controlled Trials
Randomized Controlled Trials
 
clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and design
 
6-study designs.pptx
6-study designs.pptx6-study designs.pptx
6-study designs.pptx
 
Randomized Controlled Trial
Randomized Controlled Trial Randomized Controlled Trial
Randomized Controlled Trial
 
Randomized Controlled Trial
Randomized Controlled TrialRandomized Controlled Trial
Randomized Controlled Trial
 
Randomized CLinical Trail
Randomized CLinical TrailRandomized CLinical Trail
Randomized CLinical Trail
 
Experimental Studies
Experimental StudiesExperimental Studies
Experimental Studies
 
Surgical_audit_&_research_mm (1).ppt
Surgical_audit_&_research_mm (1).pptSurgical_audit_&_research_mm (1).ppt
Surgical_audit_&_research_mm (1).ppt
 
experimental study.pptx
experimental study.pptxexperimental study.pptx
experimental study.pptx
 
Analytic upto surviellance
Analytic upto surviellanceAnalytic upto surviellance
Analytic upto surviellance
 
8-Clinical Trial Studies
8-Clinical Trial Studies8-Clinical Trial Studies
8-Clinical Trial Studies
 
biostatists presentation
biostatists presentationbiostatists presentation
biostatists presentation
 
Epidemiological concept
Epidemiological conceptEpidemiological concept
Epidemiological concept
 
Blinding in RCT the enigma unraveled
Blinding in RCT the enigma unraveledBlinding in RCT the enigma unraveled
Blinding in RCT the enigma unraveled
 
Random control trial RCT community medicine .pptx
Random control trial RCT community medicine  .pptxRandom control trial RCT community medicine  .pptx
Random control trial RCT community medicine .pptx
 
CASE CONTROL STUDY.ppt
CASE CONTROL STUDY.pptCASE CONTROL STUDY.ppt
CASE CONTROL STUDY.ppt
 
4.1 case-control and cohort.pdf
4.1 case-control and cohort.pdf4.1 case-control and cohort.pdf
4.1 case-control and cohort.pdf
 
Clinical trial design
Clinical trial designClinical trial design
Clinical trial design
 

Más de Manisha Malik

Más de Manisha Malik (8)

critical review MMR
critical review MMRcritical review MMR
critical review MMR
 
Viral hepatitis
Viral hepatitisViral hepatitis
Viral hepatitis
 
ug class environment 5n6
ug class environment 5n6ug class environment 5n6
ug class environment 5n6
 
ug class environment 4
ug class environment 4ug class environment 4
ug class environment 4
 
ug class environment 1
ug class environment 1ug class environment 1
ug class environment 1
 
us class environment 2n3
us class environment 2n3us class environment 2n3
us class environment 2n3
 
Ug class dengue
Ug class dengueUg class dengue
Ug class dengue
 
ARSH pg seminar
ARSH pg seminarARSH pg seminar
ARSH pg seminar
 

Último

Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 

Último (20)

Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 

Randomized trial seminar

  • 2. 0 Background 0 Experimental studies 0 Designs of RCT 0 Types of RCT 0 Steps in conducting RCT 0 Ethical issues 0 Pros & Cons 0 Example
  • 3. 0 Both in public health and in clinical practice, the main objective is to modify the natural history of disease so as to prevent or delay death or disability and to improve the health of patient or the population. 0 The challenge is to select the best available preventive or therapeutic measure to achieve this goal. 0 To do so, studies are carried out that determine the value of these measures.
  • 4. Galen(129-c.199ce) gave one of his potions to a lot of patients: some recovered, some died. He thought that was evidence that the potion worked. All who drink of this treatment recover in short time, Except those whom it did not help, who will die ,It is obvious, therefore, that it fails only in incurable cases. 0 The problem with Galen’s line of reasoning is that no experiment could disprove it . He could call any treatment superior by claiming that evidence against it doesn’t count.
  • 5. 0 In 1537,AMBROISE PARÉ conducted unplanned trials in the treatment of battle wounds. 0 One day after winning a battle, there were numerous wounded for him to treat. 0 Due to lack of boiling oil which was a standard treatment at that time, he used digestive made of egg yolk, rose oil & turpentine and found it to work better than boiling oil. 0 Such trials have been the instruments of development of medicine from a long time.
  • 6. 0 The first instance of random allocation of patients to experimental and control conditions is attributed to James Lind, a naval surgeon, in 1747. 0 Lind randomly assigned 12 sailors to 6 different treatments for scurvy. The two patients who were given lemons and oranges recovered most quickly, suggesting a beneficial effect of citrus.
  • 7. Randomization was Contributed by statistician R.A. Fisher in agriculture in 1923. Randomized plots of crops to receive different treatments
  • 8. 0 The first RCT in medicine is credited to Sir A. Bradford Hill, an epidemiologist for England's Medical Research Council. 0 The trial, published in the British Medical Journal in 1948, tested whether streptomycin is effective in treating tuberculosis. 0 First, he simply alternated the assignment of hospital admissions to drug versus control .Later he recognized it led to selection bias because the sequence was too easy to predict. That realization led to the use of a random numbers table to generate the numeric series by which patients would be assigned to conditions.
  • 9. 0 Involve an active attempt 0 Types  With patients as unit of studyCLINICAL TRIALS With healthy people as unit of study FIELD TRIALS/ COMMUNITY INTERVENTION STUDIES With communities as unit of study COMMUNITY TRIALS
  • 10. 0 Types RANDOMIZED CONTROLLED TRIALS Those involving a process of ‘RANDOM ALLOCATION’ Non RANDOMIZED CONTROLLED TRIALS Those departing from ‘strict randomization’ for practical purposes a. Cross-sectional comparison: e.g. to comparable communities or groups b. Temporal comparison: e.g. before and after the intervention c. Combinations of the above: e.g. time-series analysis in community trial.
  • 11. In a randomized controlled trial, Participants are assigned to treatment conditions at random (i.e., they have an equal probability of being assigned to any group). Procedures are controlled to ensure that all participants in all study groups are treated the same except for the factor that is unique to their group. The unique factor is the type of intervention they receive.
  • 12. Primary goal 0 to test whether an intervention works by comparing it to a control condition, usually either no intervention or an alternative intervention. Secondary goals may include: 0 identify factors that influence the effects of the intervention (i.e., moderators) 0 understand the processes through which an intervention influences change (i.e., mediators or change mechanisms that bring about the intervention effect)
  • 14. 0 Concurrent parallel study design 0 Cross-over type of study design 0 Factorial design 0 Cluster design
  • 15. 0 Classical clinical trial approach 0 Two study groups
  • 16. 0 Assumption of ‘no carryover effects’ is difficult to test 0 Needs to determine appropriate length of washout period. 0 “Period”effects : Progression of disease, Dropouts 0 Will patient do better on drug A or drug B? 0 Removes “patient effect” reducing variability and increasing precision of estimation
  • 17. 0 Major concern: interaction of interventions 0 Patients must be willing and able to take any of the treatment combinations 0 Optimal dose modification strategy for toxicity may be hard to determine 0 Evaluates multiple factors simultaneously
  • 18. 0 Groups or clusters randomly assigned, not individuals. E.g. : villages, classrooms , platoons 0 focus on effectiveness,outcomes under conditions of actual use. 0 more appropriate for the evaluation of interventions such as family-based dietary interventions,community-based health promotion initiatives 0 or educational interventions.
  • 19. 0 Clinical trials 0 Preventive trials 0 Risk factor trials 0 Cessation experiments 0 Trial of etiological agents 0 Evaluation of health services
  • 20. 1. Drawing up a protocol 2. Selecting reference and experimental populations 3. Allocation of study subjects: Randomization 4. Intervention / manipulation 5. Follow –Up 6. Assessment of Outcome
  • 21. 0 One of the essential feature of RCT is that it is conducted under a strict Protocol. 0 Once protocol is evolved, it should be strictly adhered to throughout the study. Prevents bias and reduces source of errors in the study. 0 Preliminary or pilot test runs of protocol can be held so see whether it contains any flaw. 0 Final version of protocol should be agreed upon by all concerned before the trial begins.
  • 22. 0 Aims & Objectives of the study 0 Questions to be answered 0 Criteria for selection of study & control group 0 Size of Sample 0 Procedure for allocation of subjects into study & control Group 0 Interventions to be applied-when ,where ,how and what kind of subjects 0 Standardization of working procedures and schedules 0 Responsibilities of parties involved in trial 0 Evaluation of outcome of study
  • 23. I. Reference /Target Population:  It is the population to which findings of the trial ,if found successful , are applicable.  e.g. whole population, population of school children, population of a city, industrial workers or social groups II. Experimental /Study Population:  derived from reference population.  Ideally, it should be chosen randomly from reference population so that it is representation of reference population. Otherwise it may not be possible to generalize the findings of the study to reference population.
  • 24. 0 Inclusion & exclusion criteria : for determining who will or will not be included in the study must be spelled out with great precision, and in writing. To ensure the replicability by others, just like with laboratory experiments
  • 25. 0 To derive a causal inference regarding relationship of intervention and outcome, comparison is important. 0 Types of controls : Historical Simultaneous nonrandomized controls Randomized controls
  • 26. 0 Comparison group from past. 0 We go back to records of patients who were treated before new treatment became available. 0 simple Demerit: 0 Comparability can not be assured 0 Quality : Data for medical purpose not for research purpose 0 Changes in many factors over calendar time 0 Recall bias
  • 27. 0 Day of month of admission-odd/even days 0 Alternate assignment into study &control group Predictable by investigator- selection bias
  • 28. 0 Randomization - a statistical procedure by which the participants are allocated to “Study” and “Control” groups. 0 The critical element of randomization is the unpredictability of the next assignment. 0 It makes RCT the gold standard design for performing clinical trials.
  • 29. Flipping a coin? Rolling dice? Shuffling cards? Table of random numbers computer random number generators • Random • Reproducible Preferable & recommended • Random but tempt investigators toward non-randomness • Adequate methods but not optimal • Cannot be checked – no audit trail Not recommended
  • 30. 0 the probability of being assigned to any intervention stays constant over the course of the trial 0 the allocation probability changes in response to the balance, composition, or outcomes of the groups 0 controversial because they allocate patients not purely at random 0 Aim: increase the sample's probability of being assigned to the best treatment FIXED ALLOCATION PROCEDURES ADAPTIVE PROCEDURES
  • 31. 1. Simple(complete) randomization 2. Permuted block randomization 3. Balanced permuted block randomization 4. Stratified randomization 1. Minimization Adaptive Randomization i. Biased Coin Randomization ii. Urn Randomization 2. Response Adaptive Randomization i. "Play-the-winner" procedure FIXED ALLOCATION PROCEDURES ADAPTIVE PROCEDURES
  • 32. 0 Elementary form of randomization, in which, every time when there is an eligible participant, the investigator flips a coin to determine whether the participant goes into the intervention or control group. 0 A limitation is that random assignment is truly random. A random process can result in the study winding up with different numbers of subjects in each group. This is more likely to happen if sample size is small
  • 33. • Characters of ‘A completely random sequence of digits’ • Each digit occurs equally frequently in the whole sequence • Adjacent (set of) digits are completely independent of one another • A table of random digits • Behaves as a finite section from a completely random series • Randomness is a property of the table as a whole • Different numbers in the table are independent
  • 34. 00–04 05–09 10–14 15–19 00 56348 01458 36236 07253 01 09372 27651 30103 37004 02 44782 54023 61355 71692 03 04383 90952 57204 57810 04 98190 89997 98839 76129 05 16263 35632 88105 59090 06 62032 90741 13468 02647 07 48457 78538 22759 12188 08 36782 06157 73084 48094 09 63302 55103 19703 74741 Take Any Direction …have to mention this chosen direction in procedureMention corresponding row & column in procedure
  • 35.  Suppose we want to compare 2 treatments(A & B) Random Number Table can be used in a no. of ways: a) we will consider every odd number an assignment to A and every even number an assignment to B b) we could say that digits 0 to 4 would be treatment A, and digits 5 to 9 treatment B. c) If we are studying three groups, we could say that digits 1 to 3 are treatment A, digits 4 to 6 treatment B, digits 7 to 9 treatment C, and digit 0 would be ignored. d) Prepare a series of opaque envelopes that are numbered sequentially on the outside: 1, 2, 3, 4, 5, and so on.
  • 36. 542-04-#37 0 Simple randomization does not guarantee balance over time in each realization. 0 Patient characteristics can change during recruitment (e.g. early pts sicker than later). 0 Restricted randomizations guarantee balance 1. Permuted-block 2. Biased coin (Efron) 3. Urn design (LJ Wei)
  • 37. 0 Blocked randomization reduces the risk that different numbers of people will be assigned to the treatment (T) and control (C) groups. 0 Patients are randomized by blocks. 0 The order is chosen randomly at the beginning of the block. 0 In randomly permuted blocks, there are several block sizes (e.g., 4, 6, and 8), and the block size and specific order are chosen randomly at the beginning of each block.
  • 38. Example 0 Block size 2m = 4 2 Trts A,B }  4C2 = 6 possible 0 Write down all possible assignments 0 For each block, randomly choose one of the six possible arrangements 0 {AABB, ABAB, BAAB, BABA, BBAA, ABBA} ABAB BABA ...... Pts 1 2 3 4 5 6 7 8 9 10 11 12
  • 39. Advantage 0 A balance in the number of cases assigned to T versus C at any point in the trial (which could be valuable if the trial needs to be stopped early). Disadvantage 0 with fixed blocks, predictability of the group assignment of patients being randomized late in the block by research staff . reduced by using the method of randomly permuted blocks and blind ing of research staff to the randomization process .
  • 40. 0 To ensure that the treatment and control groups are balanced on important prognostic factors that can influence the study outcome (e.g., gender, ethnicity, age, socioeconomic status). 0 Before doing the trial, the investigator decides which strata are important and how many stratification variables can be considered given the proposed sample size. 0 A separate simple or blocked randomization schedule is developed for each stratum. 0 Large trials often use randomly permuted blocks within stratification groups.
  • 42. o Minimization corrects (minimizes) imbalances that arise over the course of the study in the numbers of people allocated to the treatment and control. o An attempt to resolve the problem of empty strata when trying to balance on many factors with a small number of subjects o Balances Trt assignment simultaneously over many strata. o Used when the number of strata is large relative to sample size as stratified randomization would yield sparse strata. o Logistically more complicated
  • 43. o In this procedure, if the imbalance in treatment assignments passes some threshold, the allocation is changed from chance to a bias in favor of the under-represented group. o For example... If after 10 randomizations, there are 7 patients assigned to intervention and 3 assigned to control, the coin toss will become biased. o Then, rather than having 50/50 chance of being assigned to either condition, the next patient will be given a 2/3 chance of being assigned to the under-represented condition and a 1/3 chance of being assigned to the overrepresented one. o This procedure requires keeping track of imbalances throughout the trial. In smaller trials, imbalances can still result
  • 44. 0 This procedure tries to correct imbalances after each allocation. 0 For example... 0 The investigator starts with off with an urn containing a red ball and a blue ball to represent each condition. 0 If the first draw pulls the red ball, then the red ball is replaced together with a blue ball, increasing the odds that blue will be chosen on the next draw. This continues, replacing the chosen ball and one of the opposite color on each draw. 0 The procedure works best at preventing imbalance when final sample size is small.
  • 45. 542-04-#46 0 Stratified Randomization 0 Covariate Adaptive 0 Pocock & Simon
  • 46. 542-04-#47 0Goal is to balance on a number of factors but with "small" numbers of subjects 0Example .., if at some point Trt A has more older patients that Trt B, next few older patients should more likely be given Trt B until "balance" is achieved 0Several risk factors can be incorporated into a score for degree of imbalance B(t) for placing next patient on treatment t (A or B) 0More complicated to implement
  • 47. Study type Randomization Large studies Blocked Large, Multicentre studies Stratified by centre Small studies Blocked and Stratified by centre Large number of Prognostic factors Minimization Large studies Stratified analysis without stratified randomization
  • 48. • Actual randomization should be delayed until just prior to initiation of therapy after consenting. • This prevents randomizing participants who drop out before participating in any of the study. • This is important because everyone who gets randomized needs to be included in the study's analysis.
  • 49. 1. Sequenced sealed envelopes (prone to tampering!) 2. Sequenced bottles/packets 3. Phone call to central location - Live response - Voice Response System 4. One site PC system 5. Web based Best plans can easily be messed up in the implementation
  • 50. 0 Allocation concealment means that the person who generates the random assignment remains blind to what condition the person will enter. 0 Preferably, randomization should be completed by someone who has no other study responsibilities. Often, the study statistician assumes this role. 0 If allocation is not concealed, research staff is prone to assign "better" patients to intervention rather than control, which can bias the treatment effect upward by 20-30%
  • 51. • Deliberate application or withdrawal or reduction of the suspected causal factor as laid down in the protocol • This manipulation creates : Independent variable (drug, vaccine or a new procedure): whose effect is determined by measurement of final outcome. Dependent variable: final outcome (incidence of disease , survival time , recovery time)
  • 52. 0 Prognostic profile at entry 0 Treatment (Assigned & Received) 0 Follow-up  Attrition 0 Outcome  Outcome measurement  Reliability and validity of outcome measures
  • 53. 0 Attrition: refers to a rate of loss of participants from the study that differs between the intervention and control groups. 0 It may compromise  internal validity by altering the random composition of groups and their equivalence.  statistical validity by reducing sample size and power or by systematically altering the variability within samples.  External validity due to the potential for attrition to limit the generalizability of results to only those who are retained in a study.
  • 55. 0 An adverse event (AE) is an undesirable health occurrence that occurs during the trial and that may or may not have a causal relationship to the treatment. 0 A serious adverse event (SAE) is defined as something life- threatening, requiring or prolonging hospitalization and/or creating significant disability. 0 E.g. A suicide attempt -- an SAE in a study of any treatment. 0 The SAE needs to be reported regardless of whether it bears any relationship to the treatment or the problem being studied 0 Depending on the severity and frequency of adverse events, investigators and data safety monitors may have to decide to terminate the trial prematurely.
  • 56. Every Adverse event needs to be reported!
  • 57. 0 Which participants will be analyzed?  Intention to treat  Per protocol analysis 0 Subgroup Analyses 0 Statistical Power of study 0 Data Analytic Techniques  Continuous Outcome Variables  Categorial Outcome Variables
  • 58. 0 Basic Principle - “As randomized, so analyzed” 0 Includes all randomized patients in the groups to which they were randomly assigned, regardless of their adherence with the entry criteria, regardless of the treatment they actually received, and regardless of subsequent withdrawal from treatment or deviation from the protocol…..(Lloyd) Fisher et al., 1990. 0 The ITT analysis addresses the question of pragmatic hypothesis– the effectiveness of therapy i.e whether the study treatment, if made available to the population, would be superior to an alternative intervention.
  • 60. 0 the opposite end of the spectrum from ITT analysis 0 includes in the analysis only those cases who completed treatment. 0 Its results represent the best case treatment results that could be achieved if the study sample were retained and remained compliant with treatment. 0 Should not be used alone/main analysis
  • 62. 0 Planned subgroup analyses. In a few instances, a study may have been designed and powered to test whether a treatment works better for one demographic group (e.g., females) than another (e.g., males). In that case, testing a hypothesized treatment by demographic group interaction would be a primary aim that definitely needs be tested. 0 Exploratory subgroup analyses. More often, many different treatment-by-subgroup interactions will be explored. Those analyses can support hypothesis generation. The important caveat is the need to remember that unplanned subgroup analyses are done in the context of discovery rather than confirmation. Any findings require replication in another trial.
  • 63. 0 Power is ability to find a difference when a real difference exists. 0 The power of a study is determined by three factors:  Alpha level.  Sample size.  Effect size: • Association between DV and IV • Separation of Means relative to error variance.
  • 64. 0 Sometimes we will incorrectly fail to reject the null hypothesis – a type II error. 0 There really is an effect but we did not find it 0 Statistical power is the probability of detecting a real effect 0 More formally, power is given by: 1-  where  is the probability of making a type II error 0 In other words, it is the probability of not making a type II error
  • 65. 0 By making alpha less strict, we can increase power. (e.g. p < 0.05 instead of 0.01) 0 However, we increase the chance of a Type I error.
  • 66. 0 One of the most useful aspects of power analysis is the estimation of the sample size required for a particular study 0 Too small a sample size and an effect may be missed 0 Too large a sample size too expensive a study 0 Different formulae/tables for calculating sample size are required according to experimental design
  • 69. 0 n = the sample size required in each group (double this for total sample) 0 σ = standard deviation, of the primary outcome variable 0 δ= size of difference of clinical importance 0 π 1 = first proportion 0 π 2 = second proportion 0 zơ/2=depends on desired significance level 0 Zβ=depends on desired power
  • 70. 0 As the separation of means increases, the power of study increases. 0 As the variability about a mean decreases power also increases
  • 71. Continuous outcome measures((e.g. symptom severity) 0 Analysis of Variance (ANOVA) and its Variants and Extensions Alternative Analyses 0 Latent Growth Models 0 Growth Mixture Models 0 Multi-level Models Categorial outcome measures(e.g. being hospitalized or quitting smoking ) 0 Generalized estimating equations (GEE) 0 Survival analysis
  • 72. • Dichotomization: Common analyses of RCT data require outcomes to be classified as either "present" or "absent." • Some outcomes such as death, stroke, or pregnancy are naturally dichotomous (present or not). • Sometimes events are dichotomized as a "success" or a "failure" instead of "present" and "absent." • Other outcomes that are naturally continuous (e.g., length of hospital stay, blood pressure, pain score) can be dichotomized by the selection of a “cutoff” score that separates successes from failures. • A "two by two" table often summarizes results
  • 73. Blinding is an attempt to reduce bias arising out of errors of assessment a) Open trials:All participants and investigators know who is getting which interventionE.g. medical vs. surgical treatments b) Single blind trial: Participant not aware c) Double blind trial: Neither doctor/investigator nor the participant is aware. d) Triple blind trial: Doctor/investigator , participant and the person analyzing the data are all not aware of the assigned tt
  • 74. Concealment of allocation Blinding/Masking 0 to protect the randomization process before the subject enters the trial. 0 ALWAYS feasible 0 If not done, results in selection bias(treatment assignment is no longer truly random) 0 After trial begins. 0 Blinding is not always feasible 0 If not done, can result in patients biasing their responses because of their knowledge of treatment; biased outcome assessment because investigators have knowledge of treatment
  • 75. 0 Estimation with Statistical Significance Testing 0 Assessing the Effect Size of an Intervention 0 Assessing Clinical Significance
  • 76. Estimation with Statistical Significance Testing 0 Whether the effect of a treatment reaches a conventional significance level (p <.05) depends heavily on factors such as sample size. Assessing the Effect Size of an Intervention 0 An effect size describes the magnitude of an intervention's effect on the study outcome. 0 In the case of RCTs, the effect size represents the magnitude of the difference between the control and intervention conditions on a key outcome variable adjusted for the standard deviation of either group.
  • 77. Assessing Clinical Significance 0 When testing interventions that address health problems The proportion of patients who move from exhibiting clinical or dysfunctional levels of symptoms/behavior to functional levels. The Number Needed to Treat (NNT) expresses the number of patients who need to receive the intervention to produce one good outcome compared to control. NNT is a widely used index of clinical significance NNT= 1_ _____ (Rate in untreated gp)-(Rate in treated gp)
  • 78. Assessing Clinical Significance 0 When testing interventions that address health problems 0 Once outcomes have been dichotomized, six statistical measures are used to describe the treatment effect:- • Control Event Rate (CER) & Experimental Event Rate (EER) • Absolute Risk Reduction (ARR) & Number Needed to Treat (NNT) • Relative Risk (RR) & Relative Risk Reduction (RRR)
  • 79. Assessing Clinical Significance 0 CER = number of events in ctrl group/number of subjects in ctrl group 0 EER = number of events in exp group/number of subjects in exp group 0 ARR = CER – EER 0 The Number Needed to Treat (NNT) expresses the number of patients who need to receive the intervention to produce one good outcome compared to control. NNT= 1/ARR 0 RR represents the fraction of the original risk that remains with intervention.RR=EER/CER 0 RRR represents the fraction of the original risk that is removed with intervention.RRR=ARR/CER
  • 80. CER & EERExp (MgSO4) Ctrl (placebo) Row totals: CP (+) 20 38 58 CP (-) 1021 1057 2078 Column totals: 1041 1095 2136 Interpretation: 3.5% of the infants born in the control group (without MgSO4) developed moderate to severe cerebral palsy. CER = number of events in ctrl group number of subjects in ctrl group CER = 38 1095 = 0.035 = 3.5% Interpretation: 1.9% of the infants born in the experimental group (with MgSO4) developed moderate to severe cerebral palsy. EER = number of events in exp group number of subjects in exp group EER = 20 1021 = 0.019 = 1.9% Control Event Rate Experimental Event Rate
  • 81. ARR & NNTExp (MgSO4) Ctrl (placebo) Row totals: CP (+) 20 38 58 CP (-) 1021 1057 2078 Column totals: 1041 1095 2136 Interpretation: Use of MgSO4 reduced the rate of moderate to severe cerebral palsy by 1.6 percentage points. Interpretation: Between 62 and 63 pre-term mothers need to be treated in order to avoid one additional case of moderate to severe cerebral palsy. NNT= 1 ARR NNT = 1 0.016 = 62.5 Absolute Risk Reduction Number Needed to Treat ARR = CER – EER ARR = 3.5% – 1.9% ARR = 1.6% Notice how the units for CER & EER are "events per person" and the units for NNT is "people per event." This matches the intuitive interpretation of ARR & NNT.
  • 82. RR & RRRExp (MgSO4) Ctrl (placebo) Row totals: CP (+) 20 38 58 CP (-) 1021 1057 2078 Column totals: 1041 1095 2136 Interpretation: Use of MgSO4 reduced the risk of moderate to severe CP by 46% of its original value. CER RRR = ARR 0.035 0.016 RRR = = 0.46 = 46% Relative Risk Relative Risk Reduction Interpretation: Use of MgSO4 reduced the risk of moderate to severe CP to 54% of its original value. CER RR= EER 0.035 0.019 RR = = 0.54 = 54% RR represents the fraction of the original risk that remains with MgSO4. RRR represents the fraction of the original risk that is removed with MgSO4.
  • 85. 0 The Consolidated Standards of Reporting Trials (CONSORT) has become the gold standard for reporting the results of RCTs. 0 A checklist and flow diagram. 0 first published in 1996 and updated in 2001 and 2010. 0 Extensions of the CONSORT Statement have been developed for other types of study designs, interventions and data.
  • 89. 0 Investigators are responsible to uphold ethical standards and guidelines 0 Declaration of Helsinki. Developed by the World Medical Association, this set of ethical principles guides medical researchers in conducting research on human subjects.
  • 90. Some procedures for safeguarding human subjects include: 0 Informed consent procedures 0 Procedures to safeguard confidentiality 0 Protocols to preserve safety and address adverse events 0 Reporting study results
  • 91. 0 Random assignment and the use of a control condition ensure that any extraneous variation not due to the intervention is either controlled experimentally or randomized. That allows the study's results to be causally attributed to differences between the intervention and control conditions. 0 In sum, the use of an RCT design gives the investigator confidence that differences in outcome between treatment and control were actually caused by the treatment, since random assignment (theoretically) equalizes the groups on all other variables.
  • 92. Drawbacks of conducting an RCT are: 0 Time- and energy- intensive, Expensive 0 Losses to follow-up, lack of perfect blinding, and other problems often affect RCTs in the field of public health, 0 “effect modification”--when the intervention–outcome association varies according to the presence of external characteristics. 0 “behavioral effect modification,”(institutional, provider, and recipient behaviors)“biological effect modification.”
  • 93. 0Unnecessary if: 0 Clearly successful intervention 0 Previous RCT’s or meta-analyses 0Impractical when: 0 Unethical to randomise 0 Large number needed 0Inappropriate when: 0 Looking at prognosis 0 Looking at validity of diagnostic tests 0 Looking at quality of care
  • 94. Intervention : Modeled On The Baby-friendly Hospital Initiative
  • 96. 0 two-week zinc therapy for diarrhoea on morbidity and mortality due to diarrhoea and ALRI in a community-based cluster randomized trial (3) in the Matlab field area of ICDDR,B: Centre for Health and Population Research in Bangladesh. Thirty service areas (clusters) around Matlab Treatment Centre each with about 200 children aged 3-59 months were randomly allocated to intervention or comparison areas. One community health worker served each cluster 0 In this trial, the availability of zinc supplements, along with ORT and appropriate education programmes, was associated with significantly higher use of ORT and lower use of antibiotics. J HEALTH POPUL NUTR 2004 Dec;22(4):440-442
  • 97. 0 “Evidence-based public health” calls for a solid knowledge base on disease frequency and distribution, on the determinants and consequences of disease, and on the safety, efficacy, and effectiveness of interventions and their costs. 0 Existing standards and methods must be adapted to meet the methodological challenges of evaluating large-scale public health interventions.
  • 99. 0 Instead of having a “no treatment” control, equivalence trials test whether a new intervention is as good as (or not worse than) an established treatment with proven efficacy. 0 New intervention may have some advantage (convenience, cost) over established, but is it at least as efficacious?
  • 100. 0 People may be carrying out equivalence trials without realising it. 0 Analysis with respect to a pre-stated margin of non-inferiority (smallest clinically interesting difference) 0 ITT analysis may increase risk of type 1 error 0 Choice of outcomes important Piaggio et al., 2006, JAMA,295,1152-1160
  • 101. 0 Need to reference established efficacy of “standard” treatment 0 Hypotheses should be framed in terms of non-inferiority 0 “Margins of equivalence” should be reported
  • 102. 0 Various approaches used: 0Checklist approach 0Quality scoring system approach 0 Quality scores are complicated and tend to vary depending on the instrument used –so, not encouraged